CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...
Jiangsu Yahong Meditech Gets NMPA Approval for APL1401 Ulcerative Colitis Trial
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer based in...
Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales
China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half...
Fosun Pharma Reports Moderate Revenue Growth and Increased R&D Spend in 2023 Interim Report
Fosun Pharma (SHA: 600196) has released its 2023 interim financial report, recording revenues of RMB...
Roche’s Evrysdi Receives EC Approval for Expanded Indication in Infants with SMA
Swiss pharmaceutical giant Roche (SWX: ROG) has received regulatory approval from the European Commission (EC)...
MSD’s Keytruda Gains EC Approval for First-Line HER2-Positive Gastric Cancer Treatment
The European Commission (EC) has granted an additional indication to Merck, Sharp & Dohme (MSD;...
BMS’ Reblozyl Expands Indication to Include First-Line MDS-Related Anemia Treatment
Bristol-Myers Squibb (BMS; NYSE: BMY) has received an indication extension approval from the US Food...
HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026
The Department of Health and Human Services (HHS) in the US has released a list...
ImmunoTech Biopharm’s EAL Earns Breakthrough Therapy Designation for HCC Recurrence Prevention
The Center for Drug Evaluation (CDE) in China has indicated on its website that Immunotech...
Mabwell Bioscience Secures Deal with UNILAB for Biosimilar Humira in the Philippines
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing and supply agreement...
HanchorBio and Henlius Pharmaceutical Enter Strategic Collaboration for Immunotherapies
Taiwan-based HanchorBio has entered into a strategic cooperation framework agreement with Shanghai-headquartered Shanghai Henlius Biotech,...
Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial
Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product,...
Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials
China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...
Sandoz Expands Anti-Infective Portfolio with Acquisition of Astellas Pharma’s Antifungal Mycamine
Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition...
BMS Partners with Cellares for Automated CAR-T Cell Therapy Production
Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy...
Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification
A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached...
Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales
Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the...
Janssen Submits Indication Extension Application for Balversa in Urothelial Carcinoma Treatment
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an indication extension...
Zhejiang Huahai Pharmaceutical Receives FDA Approval for Generic Vyvanse
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced the receipt...
Antengene’s Xpovio Price Reduced by 37% in China, Aiding Patient Access
Antengene Corp., Ltd (HKG: 6996) has announced a significant price reduction for its drug Xpovio...